ANIK
Anika Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$20.40
+4.88%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$19.88
From 52W high−7.40%
Volume95283.00
Market cap$273.01M
P/E (TTM)—
P/S (TTM)2.3x
Div yield—
Key dataNov 4, 2026
Open
$19.88
From 52W high
−7.40%
Volume
95283.00
Market cap
$273.01M
ValuationView details →
P/E (Fwd)
21.7x
EV/EBITDA
94.8x
P/E (TTM)
—
RSI (14)
47.3
MomentumView details →
1D Return
+4.88%
YTD Return
+109.89%
SummaryUpdated Jun 1, 2026
Anika Therapeutics, Inc. (NASDAQ:ANIK) is a joint preservation company founded in 1983 and headquartered in Bedford, Massachusetts. The company went public in 1993 and has established itself as a specialized medical device manufacturer focused on orthopedic care solutions. Anika develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology, serving both domestic and international markets. The company has undergone significant strategic restructuring in recent years, divesting non-core assets like Arthrosurface and Parcus Medical to focus exclusively on its proprietary hyaluronic acid-based product portfolio.
Similar companies
Latest newsMore news →
Anika Therapeutics, Inc. announced that it will release its third-quarter 2026 financial results before the market opens on November 6, 2026, followed by a conference call at 8:30 a.m. ET.13d agoAnika Therapeutics, Inc. entered into a Fifth Amendment to its credit agreement, establishing a $50.0 million senior secured revolving line of credit with an option to increase to $100.0 million, maturing on July 10, 2031.114d ago